Showing results (141-150 of 186) with videos related to
Sort By:
Pageof 19
Clinical Therapeutics|May 13, 1999
Candesartan cilexetil: comparison of once-daily versus twice-daily administration for systemic hypertension. Candesartan Cilexetil Study InvestigatorsC A Zuschke, I Keys, M A Munger, et al.Journal of the American College of Cardiology|May 12, 2012
Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) programDavide Castagno, Hicham Skali, Madoka Takeuchi, et al.The American Journal of Medicine|October 17, 1983
Intravenous labetalol in the treatment of severe hypertension and hypertensive emergenciesD J Wilson, J D Wallin, N D Vlachakis, et al.The American Journal of Cardiology|September 25, 1999
Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study InvestigatorsS Oparil, J H Levine, C A Zuschke, et al.European Journal of Heart Failure|January 27, 2009
Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) programLarry A Allen, G Michael Felker, Stuart Pocock, et al.European Journal of Heart Failure|February 5, 2008
Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trialR A P Weir, John J V McMurray, Margareta Puu, et al.Diabetes Care|February 7, 2009
Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) programDavid Preiss, Sofia Zetterstrand, John J V McMurray, et al.European Journal of Heart Failure|January 24, 2014
Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-PreservedJennifer K Rogers, Stuart J Pocock, John J V McMurray, et al.The American Journal of Cardiology|March 15, 1985
Combination propranolol and bepridil therapy in stable angina pectorisW H Frishman, S Charlap, D J Farnham, et al.Circulation|December 7, 2005
Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patientsScott D Solomon, Nagesh Anavekar, Hicham Skali, et al.Pageof 19